한빛사논문
- 조회745
Jee-Young Lee1,2,*, Antonio Martin-Bastida3, Ane Murueta-Goyena4, Iñigo Gabilondo4,5, Nicolás Cuenca6, Paola Piccini7, Beomseok Jeon8,9
1Department of Neurology, Seoul National University College of Medicine, Seoul, South Korea.
2Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea.
3Department of Neurology and Neurosciences, Clinica Universidad de Navarra, Pamplona-Madrid, Spain.
4Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.
5Ikerbasque: The Basque Foundation for Science, Bilbao, Spain.
6Department of Physiology, Genetics and Microbiology, University of Alicante, Alicante, Spain.
7Division of Neurology, Department of Brain Science, Imperial College London, London, UK.
8Department of Neurology, Seoul National University College of Medicine, Seoul, South Korea.
9Seoul National University Hospital, Seoul, South Korea.
*Corresponding author.
Abstract
Parkinson disease (PD) is a progressive disorder characterized by dopaminergic neurodegeneration in the brain. The development of parkinsonism is preceded by a long prodromal phase, and >50% of dopaminergic neurons can be lost from the substantia nigra by the time of the initial diagnosis. Therefore, validation of in vivo imaging biomarkers for early diagnosis and monitoring of disease progression is essential for future therapeutic developments. PET and single-photon emission CT targeting the presynaptic terminals of dopaminergic neurons can be used for early diagnosis by detecting axonal degeneration in the striatum. However, these techniques poorly differentiate atypical parkinsonian syndromes from PD, and their availability is limited in clinical settings. Advanced MRI in which pathological changes in the substantia nigra are visualized with diffusion, iron-sensitive susceptibility and neuromelanin-sensitive sequences potentially represents a more accessible imaging tool. Although these techniques can visualize the classic degenerative changes in PD, they might be insufficient for phenotyping or prognostication of heterogeneous aspects of PD resulting from extranigral pathologies. The retina is an emerging imaging target owing to its pathological involvement early in PD, which correlates with brain pathology. Retinal optical coherence tomography (OCT) is a non-invasive technique to visualize structural changes in the retina. Progressive parafoveal thinning and fovea avascular zone remodelling, as revealed by OCT, provide potential biomarkers for early diagnosis and prognostication in PD. As we discuss in this Review, multimodal imaging of the substantia nigra and retina is a promising tool to aid diagnosis and management of PD.
논문정보
- Review Paper
- 2022년 04월 (BRIC 등록일 2022-04-26)
- 국내(교신)+국외 연구진
- 바이오·의료융합 > 뇌인지과학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
